^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Carboplatin/Cetuximab
Secondary therapy:
carboplatin
